Program
osavampator
Also written as “NBI-1065845”, “TAK-653” and “Osavampator”.
Its studies are mostly in Depressive Disorder, Major · Depressive Disorder · Depressive Disorder, Treatment-Resistant, led by 2 companies.
Drug pageOsavampator: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciencesits history only | 85 open or running | phase 3since Jan 15, 2025 | Sep 9, 2015 | Jul 2027phase 3 · NCT06911112 |
| Takeda | 10 open or running | phase 2since Oct 13, 2017 | Oct 13, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 13, 2017First study: phase 2 study in Depressive Disorder, Treatment-ResistantFirst studyNCT03312894
- Aug 6, 2023Named osavampatorINNProposed as its International Nonproprietary Name in WHO's List 129 · before, NBI-1065845, TAK-653
TargetBeta
“Glutamate receptor ionotropic AMPA positive allosteric modulator”ChEMBL 37, by rule
Studies
The one study Takeda leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03312894Depressive Disorder, Treatment-Resistant | 2 | Withdrawn | Feb 28, 2019 | 0 |
How it is read
Names in the registry
- “NBI-1065845”, 5 entries
- “TAK-653”, 3 entries
- “Osavampator”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 6 studies
- Depressive Disorder, 1 study
- Depressive Disorder, Treatment-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.